0001209191-19-007568.txt : 20190205 0001209191-19-007568.hdr.sgml : 20190205 20190205195756 ACCESSION NUMBER: 0001209191-19-007568 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190201 FILED AS OF DATE: 20190205 DATE AS OF CHANGE: 20190205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chhabra Meenu CENTRAL INDEX KEY: 0001534200 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37695 FILM NUMBER: 19569570 MAIL ADDRESS: STREET 1: 1600 FAIRVIEW AVE. E. STREET 2: SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 80 GUEST STREET STREET 2: 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-225-0096 MAIL ADDRESS: STREET 1: 80 GUEST STREET STREET 2: 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-01 0 0001445283 PROTEOSTASIS THERAPEUTICS, INC. PTI 0001534200 Chhabra Meenu C/O PROTEOSTASIS THERAPEUTICS, INC. 80 GUEST STREET, SUITE 500 BOSTON MA 02135 1 1 0 0 President and CEO Common Stock 2019-02-01 4 M 0 46875 A 97093 D Common Stock 2019-02-04 4 S 0 16478 2.9922 D 80615 D Restricted Stock Units 2019-02-01 4 M 0 46875 0.00 D Common Stock 46875 0 D Each restricted stock unit represents a contingent right to receive one share of PTI common stock. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and were made in order to pay the tax liability arising from the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.96 to $3.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The restricted stock units vested in full on February 1, 2019. /s/ Janet Smart, Attorney-in-Fact 2019-02-05